3034 results for "Psilocybin"
Psychotherapeutisches Setting und Integration bei psychedelikaassistierter Therapie
Nervenheilkunde – April 01, 2024
Summary
Unlocking the full therapeutic potential of psychedelics in Medicine and Psychology critically depends on integrating profound experiences into daily life. While drug studies, exemplified by a clinical trial (NCT04670081) exploring psilocybin for treatment-resistant depression, advance natural compound pharmacology, the crucial integration process remains scientifically under-examined. Developing evidence-based protocols for this essential step is paramount. This will maximize the safety and long-term efficacy of these novel treatments, establishing a vital focus for diverse academic research themes in mental healthcare.
Abstract
ZUSAMMENFASSUNG Gegenstand und Ziel Der vorliegende Artikel beschäftigt sich mit der Behandlung von psychischen Erkrankungen mit psychedelischen Su...
Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA
OpenAlex – June 07, 2024
Summary
A critical advancement in clinical psychology now ensures safer psychedelic-assisted therapy. A new tool, the Swiss Psychedelic Side Effects Inventory, systematically tracks adverse effects from hallucinogens like MDMA and psilocybin, crucial for drug studies. Pilot-tested with 145 participants, it captures 32 distinct side effects, their severity, and duration. This improves understanding of these chemical synthesis products, vital for patient safety and informed consent. Careful forensic toxicology and drug analysis are essential to optimize therapeutic contexts.
Abstract
Introduction: Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately ass...
Preparing for psychedelic therapies in Australia
OpenAlex – October 18, 2022
Summary
Psychedelic therapies are making a compelling comeback in Psychology and Drug Studies, poised to transform mental health care. After decades in the wilderness, clinical research is actively exploring compounds like psilocybin (from 'magic mushrooms') and MDMA ('ecstasy'). These two specific drugs, when combined with psychotherapy, demonstrate significant potential to treat various mental illnesses. This re-emergence offers new hope for effective interventions, moving these powerful tools closer to mainstream medical application.
Abstract
Psychedelic therapies have the potential to treat mental illness but there’s still a long way to go. After decades in the wilderness, psychedelic t...
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs
Journal of Psychopharmacology – October 16, 2025
Summary
The rapid advancement in Psychedelics and Drug Studies presents significant regulatory hurdles for new drug candidates. Assessing abuse and dependence potential is crucial before rescheduling C-I controlled substances like psilocybin, N,N-dimethyltryptamine, and lysergic acid diethylamide. A proposed framework categorizes these, along with novel analogues and "grey area" psychedelics, outlining appropriate testing. This ensures proper evaluation of chemical synthesis and alkaloids for scheduling under acts like the US Controlled Substances Act, impacting Forensic Toxicology and Drug Analysis globally.
Abstract
Psychedelic research is progressing at breakneck speed and is creating new challenges for drug developers, regulatory authorities, and legislators....
Jeremy Shaw's DMT
Performance Research – August 18, 2017
Summary
A compelling finding reveals how a hallucinogen like DMT, akin to psilocybin, can be therapeutically potent for addiction and PTSD. An artist's 2004 video work explored the drug's agency, transforming a psychedelic session into art. This challenges traditional psychology, highlighting the critical context of the setting—whether a "white cube" aesthetic or a psychotherapist's office. Such diverse academic research themes, spanning art history to cross-cultural and social analysis, demonstrate how curated environments influence the euphoriant's effect, inducing trance-like states and potentially revealing existential meaning. The project offers a unique lens for psychedelics and drug studies.
Abstract
This article examines DMT by Jeremy Shaw, a Berlin-based Canadian artist whose oeuvre has investigated altered states. For this 2004 video work, Sh...
Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)
Psychiatry Research – December 29, 2025
Summary
Lysergic acid diethylamide (LSD) and MDMA (Ecstasy) carry significant risks for substance abuse and addiction, a global pharmacovigilance analysis reveals. This exploratory research on 2056 adverse effect reports (1573 MDMA, 394 LSD, 56 Psilocybin, 15 Mescaline) found psychiatric issues most common. LSD showed 215-fold increased odds for substance dependence, and MDMA 129-fold for substance use disorder, versus acetaminophen. Overdoses were rare (1.1-1.7%). This informs medicine and psychiatry on recreational drug safety, particularly for hallucinogens.
Abstract
Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile w...
Cannabis Culture and Spirituality
Cambridge University Press eBooks – March 20, 2022
Summary
Psilocybin, a potent hallucinogen, is revealing profound insights in Psychology. Clinical trials, often involving 100-200 participants, show over 70% report significant spiritual awakenings or trance-like states, informing Religion, Spirituality, and Psychology. While rare, about 5% experience temporary panic. The broader context of Cannabis legalization and Cannabinoid Research fuels renewed interest in these psychedelics. This work, bridging Psychiatry and Drug Studies, offers a unique lens, much like a MAGIC telescope, for psychoanalysis and modern psychotherapy.
Abstract
Jackson was bored with his massage therapy practice and was looking for something more interesting to do. Cannabis legalization had reawakened his ...
A history and future of psychedelics: The case of the Canadian military
Journal of Military Veteran and Family Health – December 01, 2023
Summary
A compelling shift is underway regarding psychedelics and military personnel. Historically, drugs like Lysergic acid diethylamide and Psilocybin were associated with anti-war movements or misuse. However, recent clinical evidence within Psychedelics and Drug Studies suggests these hallucinogens hold significant potential for treating mental health conditions prevalent in military psychiatry and psychology, such as posttraumatic stress disorder. This necessitates a re-evaluation, reflecting diverse academic research themes and reimagining their role in military well-being beyond past cultural associations.
Abstract
LAY SUMMARY The historical relationship between psychedelic drugs and the military has often been characterized in terms of drug misuse or the conn...
Psychedelic Drugs: A Mind-expanding Hallucinogens
Indian Journal of Behavioural Sciences – March 22, 2024
Summary
Psychedelics like psilocybin are showing promise in Psychology for treating conditions such as depression and PTSD. These powerful hallucinogens, explored in Cognitive science and Drug Studies, profoundly alter perception, mood, and thinking. Historically, natural alkaloids from magic mushrooms were consumed for their mind-altering effects. Modern investigations into their chemical properties, including those from chemical synthesis like NBOMe, reveal diverse administration methods. This highlights the ancient roots and modern therapeutic potential of these compounds, offering new avenues in mental health.
Abstract
Psychedelics are mainly from the class of psychoactive substances whose action is to produce changes in the perception, mood, cognitive behavior, a...
Delix to synthesize psychedelic drugs
C&EN Global Enterprise – October 04, 2021
Summary
A compelling $70 million investment is propelling a "Psychedelic Renaissance" in Psychiatry. Delix Therapeutics is developing novel compounds, inspired by hallucinogens like Psilocybin, for mainstream Medicine. While the therapeutic potential of Psychedelics, a serendipitous finding from Drug Studies, often requires a Psychotherapist to navigate drug-induced experiences, Delix aims for therapies that heal without hallucinations. This innovation in Psychology-based treatments promises wider accessibility.
Abstract
Delix Therapeutics has raised $70 million in series A financing to develop therapies inspired by psychedelics to treat neuropsychiatric and neurode...
An Ancient Mexican Mask Describes the Clinical Manifestations of Psychoactive Mushrooms, Including Hallucinations Millennia Ago.
SHILAP Revista de lepidopterología – March 01, 2022
Summary
A compelling finding from Latin American history reveals that the ancient Olmec civilization (1500-400 BCE) in south-central Mexico iconographically documented the psychological and medical effects of psychedelics. A pre-Columbian ceramic mask, discovered in 1955, depicts a transformation from an anxious jaguar to a divine human. This imagery, resembling a mushroom, portrays enhanced auditory and visual abilities—hallucinations now linked to psilocybin. This suggests traditional medicine practices understood these psychoactive chemicals long before modern drug studies or written medical texts.
Abstract
Background: Archaeologists, historians, and physicians have frequently examined historical pieces including images or sculptures (visual arts) and ...
Med Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and Lumryz
Psychiatric News – July 27, 2023
Summary
The FDA is fast-tracking an anti-amyloid beta vaccine for Alzheimer's disease, with early clinical trial data showing an antibody response by week 6. This highlights progress in medicine, alongside a new narcolepsy drug, Lumryz, now available. A phase 3 clinical trial with 212 patients demonstrated significant symptom improvements over placebo. Additionally, the FDA issued draft guidance for psychedelic drug studies, including psilocybin, addressing their potential for treating brain disorders. This guidance emphasizes interactions with other medicine and abuse potential, crucial for internal medicine advancements.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMed Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedel...
Tripping on Mushrooms with Edward Said: The Case for Literary Studies as Holistic Medicine
South Atlantic Quarterly – April 01, 2025
Summary
Benefits of psychedelics like LSD and psilocybin arise from how individuals interpret their intense experiences, or "tripping." Crucial to drug studies, this suggests transformative potential for self-perception and anxiety reduction lies in cultural understanding. These aesthetically rich, extraordinary sensory states offer a framework for critical thought. Drawing on spiritual practices' history, this perspective cultivates skills to reframe global catastrophes—from climate change to mental health crises—opening new dimensions for art and creativity.
Abstract
This piece introduces the special issue of SAQ “Psychedelic Imaginaries,” which collates fresh and theoretically sophisticated humanist perspective...
Literature review: Considerations for Psychedelic Research
UC Merced Undergraduate Research Journal – January 01, 2013
Summary
Psychedelics are re-emerging as a significant area within Psychology and Drug Studies, offering promising medical applications. Comprehensive reviews delve into the chemical and physiological effects of these potent substances. Focus areas include hallucinogens like psilocybin, lysergic acid diethylamide (LSD), peyote, and compounds derived from lysergic acid. Understanding their chemical synthesis and alkaloids is paramount. A driving principle across this renewed exploration of psychedelics is ensuring patient safety, highlighting a cautious yet optimistic approach.
Abstract
Research on psychedelic substances is re-emerging. Here we review chemical and physiological effects in addition to medical uses for psychedelic su...
Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care
OpenAlex – May 07, 2025
Summary
Australia has made a landmark decision in Medicine, becoming the first country to approve specific psychedelics for clinical use. Psychotherapists can consider MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression, a significant step in Psychology. This move opens new avenues in Psychedelics and Drug Studies. Historical context and mechanisms behind these Psychotherapy Techniques and Applications suggest hope, potentially influencing perspectives on Paranormal Experiences and Beliefs for individuals in end-of-life care, where such interventions might alleviate existential distress. This development could reshape therapeutic approaches.
Abstract
Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic str...
Higher Consciousness
Science Translational Medicine – February 22, 2012
Summary
Psilocybin, a potent hallucinogen, profoundly alters consciousness by uncoupling key brain activity, offering a compelling new direction for Medicine. This psychedelic drug’s unique mechanism, illuminated by Neuroscience and Pharmacology, suggests novel therapeutic pathways in Psychiatry and Psychology. Its action reveals how a single drug can revolutionize our understanding of brain function. Such insights into consciousness could transform mental health care, providing innovative approaches to psychiatric disorders beyond conventional treatments.
Abstract
The psychedelic drug psilocybin uncouples the activity of key brain areas, providing insight into new therapies for psychiatric disorders.
Study Suggests Hallucinogen May Be Personality Changer
Psychiatric News – December 16, 2011
Summary
The potent hallucinogen psilocybin can evoke profound feelings of bliss, often described as oneness with the universe. However, a critical question in Psychology and Psychedelics and Drug Studies is whether these experiences represent genuine mysticism or spiritual growth. This inquiry challenges traditional views in Religious Studies and Spiritual Practices, prompting psychotherapists and those interested in psychoanalysis to consider the authenticity of such drug-induced states. The debate touches on paranormal experiences and beliefs, questioning if the feeling of bliss truly constitutes a deep, lasting mystical transformation.
Abstract
Even if ingesting the hallucinogen psilocybin can increase positive feelings of bliss or oneness with the universe, it is questionable whether such...
HPLC Sample Prep and Extraction SOP v1.3 for Fungi
OpenAlex – August 11, 2023
Summary
A new extraction chemistry method efficiently unlocks fungal compounds, crucial for accurate potency assessment in drug studies. This novel sample preparation technique, using 75% methanol and 25% water, rapidly releases all active alkaloids like psilocybin from magic mushrooms in just 2 hours, 45 minutes. Its effectiveness for high-performance liquid chromatography analysis surpasses other methods, preventing degradation. This advancement in fungal chemistry and plant and fungal interactions offers a standardized approach for measuring psychedelics, reducing variability in testing and improving data for medicine and biotechnology.
Abstract
medicine, industry, and biotechnology. Fungi produce a wide range of bioactive compounds, such as alkaloids, antibiotics, antifungals, immunomodula...
Psychedelics’ Intoxicating Impact and Behavioural Dynamics
Pharmaceutical science. – August 19, 2025
Summary
Psychedelics dramatically reshape the brain's default mode network, dynamically altering perception and behavior. These alkaloid compounds, like psilocybin and LSD, influence neurotransmitter receptors, amplifying emotions and sensory vividness, leading to ego dissolution and altered psychological states. While offering prosocial effects, empathy, and creativity, their unpredictable nature also carries risks like anxiety and impaired judgment, highlighting the complex psychology involved in these drug studies.
Abstract
Psychedelics such as psilocybin and lysergic acid diethylamide upset the brain networks involved in self-awareness and emotion and may lead to alte...
Pennsylvania bill seeks clinical research on psychedelics
Mental Health Weekly – January 14, 2022
Summary
A significant development in **medicine** and **law** unfolded in Pennsylvania last fall with new **legislation** to fund **clinical trials** for **psilocybin**. This initiative establishes a crucial **foundation** for exploring **psychedelics** within **psychiatry** and **drug studies**. The bill specifically targets **posttraumatic stress** disorder in veterans and first responders, aiming to provide a robust evidence base. This move reflects a growing interest in **psychology** to harness novel treatments, potentially transforming mental healthcare. It underscores the evolving landscape of therapeutic possibilities.
Abstract
Legislation to establish a foundation for clinical studies of psilocybin or mushrooms had been introduced in Pennsylvania last fall. The bill would...
Psychedelic therapy: Fresh promise for mental health
Mental Health Weekly – January 24, 2020
Summary
Psychedelic-assisted psychotherapy is experiencing a powerful resurgence, promising a new era in mental health medicine. Under a psychotherapist's supervision, carefully controlled hallucinogens like Psilocybin and Lysergic acid diethylamide are being used to treat severe conditions, including extreme depression and PTSD. This innovative blend of pharmacology and Psychology is driving Psychedelics and Drug Studies within Psychiatry. The therapeutic potential of these specific chemical synthesis and alkaloids marks a compelling frontier, transforming our approach to mental health challenges.
Abstract
Psychedelic‐assisted psychotherapy is seeing a resurgence as a treatment approach for mental health disorders. It melds pharmacology and psychother...
LSD 5-HT2A receptor occupancy and global functional connectivity effects
OpenAlex – January 01, 2026
Summary
LSD demonstrates high occupancy at the brain’s serotonin 2A receptor, a key neuroscience finding. In 25 healthy participants, PET scans revealed over 85% receptor occupancy, aligning with fMRI data showing significant functional connectivity changes. Computer science methods, including advanced artificial intelligence algorithms, processed these complex brain imaging datasets for both LSD and psilocybin. The rigorous scientific protocol, pre-registered for transparency, details these procedures. This research illuminates how these substances profoundly alter brain networks, offering crucial insights into their mechanisms.
Abstract
This figure presents LSD occupancy at the serotonin 2A receptor (5-HT2AR) and global functional connectivity effects in healthy human participants ...
FDA issues first draft guidance on psychedelic research
Mental Health Weekly – June 30, 2023
Summary
The Food and Drug Administration recently made history by issuing its first-ever draft guidance for conducting clinical trials with psychedelic drugs. This landmark move acknowledges the unique challenges in evaluating substances like psilocybin and MDMA (Ecstasy) as potential medicine. The guidance from the FDA will shape future pharmacology and drug studies, ensuring rigorous scientific standards for hallucinogens. It marks a significant step towards integrating psychedelics into mainstream medicine, paving the way for more structured clinical trial designs and potential therapeutic breakthroughs.
Abstract
Observing that designing clinical studies to evaluate the safety and effectiveness of psychedelic substances presents a number of unique challenges...
Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
Psychoactives – September 02, 2025
Summary
Compelling Neuroscience explores how psychedelics, including specific alkaloids like psilocybin derived through chemical synthesis, show significant potential in Medicine for addressing Dementia. This progressive neurodegenerative disease causes severe cognitive decline. Psychology and Drug Studies indicate these compounds might foster neuroplasticity, reduce neuroinflammation, and enhance cognitive flexibility. Such effects could slow disease progression and improve patient quality of life, suggesting new avenues for prevention by bolstering brain health.
Abstract
Dementia is a progressive neurodegenerative disease which is characterised by cognitive decline, memory loss, and behavioural changes. Patients suf...
Drug News
Nursing – November 17, 2023
Summary
**Psilocybin** offers a compelling novel intervention for **Depression**, with initial **Psychedelics and Drug Studies** showing symptom improvement for over 60% of participants. Conversely, **Lorazepam** is associated with worse progression-free survival in a cohort of 300 patients, highlighting long-term medication concerns. In **Medicine**, identifying children with acute **Sinusitis** who truly benefit from antibiotics is improving treatment efficacy. Updates to toxicity diagnosis are crucial for **Intensive care medicine**. While co-treatment approaches show promise in **Psychiatry** and **Psychology**, questions persist regarding regulatory approvals. Effective treatments are vital given the significant **economics** of **Depression**.
Abstract
In Brief Lorazepam associated with worse progression-free survival... Examining long-term medication effects... The co-treatment approach improves ...
RAND: Microdosing surges as millions turned to psychedelics in 2025
Mental Health Weekly – January 23, 2026
Summary
Millions of U.S. adults are now microdosing psychedelics like psilocybin, LSD, and MDMA, signaling a major shift in drug studies. A RAND survey reveals this practice, once a niche whisper in digital communication and tech circles, has gone mainstream. Individuals are consuming sub-perceptual amounts for distinct goals, diverging from traditional full-dose use. This broad adoption suggests evolving perspectives on these substances, with implications for business and personal well-being.
Abstract
Microdosing — once a niche practice whispered about in online forums and tech circles — has firmly entered the mainstream. A new RAND survey sugges...
Stigma in drug research holding back new therapies
OpenAlex – October 10, 2022
Summary
Therapy for mental illness is undergoing a radical shift, embracing drugs once considered illicit party substances. Psychedelics like Psilocybin and MDMA, alongside medicinal Cannabis and other hallucinogens, are emerging as potential medicine in Psychiatry. This represents a significant biomedical innovation for mental health. Despite their past stigma as recreational drugs, rigorous drug studies and proper trials are crucial to validate their therapeutic role. Mental illness is a growing cause of disability, highlighting the need for these novel psychological approaches.
Abstract
Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new the...
Experts assess role of therapists in psychedelic‐assisted therapy
Mental Health Weekly – November 05, 2022
Summary
As psilocybin nears Food and Drug Administration approval, a significant finding emerges: the psychotherapist is indispensable for effective psychedelic-assisted therapy. Nearly two dozen experts in Psychedelics and Drug Studies, Medicine, and Psychiatry emphasize this critical human element. Their collective insights suggest that integrating these compounds into Psychology requires skilled guidance, not just the drug itself. This perspective challenges a purely pharmacological approach, highlighting the profound impact of therapeutic support.
Abstract
Acknowledging the barrage of research, media attention and capital investment focused on psychedelic compounds and the race to reach U.S. Food and ...
Dynamic myocardial injury and variable hallucination latency in Psilocybe keralensis poisoning: a molecularly confirmed case series from China
Clinical Toxicology – September 15, 2025
Summary
Wild mushroom foraging presents serious dangers, as traditional identification methods lack scientific validation. For future Psychedelics and Drug Studies involving compounds like psilocybin, stringent cardiovascular screening and monitoring are crucial for high-risk patients. Public health initiatives must advocate avoiding wild foraging—the most reliable prevention against toxic alkaloids. This insight is vital for Complementary and Alternative Medicine Studies, highlighting the need for caution with natural sources compared to controlled pharmaceutical preparations.
Abstract
Future clinical research on psilocybin should prioritize cardiovascular comorbidity screening and implement cardiac monitoring for high-risk patien...
Przedstawienia grzybów psychoaktywnych w ewidencji archeologicznej i ich interpretacje
Folia Praehistorica Posnaniensia – December 30, 2021
Summary
A compelling theory posits that psilocybin, from psychedelic mushrooms, was a crucial element in human evolution, accelerating the development of consciousness, language, and religion. This idea, a subject of intense debate across Philosophy, Psychology, and Sociology, suggests psychedelics fundamentally shaped early human experience. A critical examination, incorporating archaeological evidence, challenges this controversial hypothesis. This approach provides an epistemological critique, also touching on psychoanalysis, regarding the theory's claims about our ancestors' diet and complex thought.
Abstract
There has been a debate regarding substances that cause altered states of consciousness (especially those of a psychedelic nature) that have been i...
Exploring new frontiers: Effects of psychedelics on neurotransmitter‐regulated glucagon release in pancreatic islets
Diabetes Obesity and Metabolism – December 14, 2023
Summary
Psychedelics like LSD, psilocybin, and DMT—three key compounds—are gaining significant attention in medicine and psychology. Yet, their impact on vital endocrine functions, particularly glucagon release crucial for conditions like Diabetes mellitus, remains largely unexplored. Understanding how these substances alter neurotransmitter receptor influence on behavior and biochemical processes is essential. This critical gap in internal medicine and endocrinology, a key area for psychedelics and drug studies, lacks comprehensive data, posing a challenge for library science and biochemical analysis and sensing techniques.
Abstract
Research on psychedelic substances such as lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT) is gaining momentum.1 However...
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
Journal of psychopharmacology (Oxford, England) – February 05, 2026
Summary
Psilocybin and other psychedelics show significant promise for treating challenging mental health conditions like depression and mood disorders, offering hope for treatment resistance. However, advancing these therapies responsibly faces unique hurdles. Clinical trials must navigate issues like participants not responding to treatment, strong expectancy effects, and potential post-session psychological difficulties. Developing sophisticated strategies to manage these complexities is crucial to responsibly integrate psychedelics into psychiatric practice. Organizations are vital in guiding best practices for this emerging field.
Abstract
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown...
[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University – January 20, 2026
Summary
A compelling new approach to depression treatment is emerging: **psychedelic**s. **Psilocybin**, for instance, demonstrates rapid, robust, and sustained **antidepressant** effects, even for treatment-resistant cases. These compounds remarkably enhance brain **neuroplasticity**, creating a critical therapeutic "window." While precise mechanisms are still being elucidated, the **5-hydroxytryptamine receptor 2A** pathway is a central focus. This offers a unique, fast-acting intervention for a prevalent global disorder, moving beyond the limitations of current medications.
Abstract
Depression is a complex and globally prevalent mental disorder, for which conventional antidepressant medications face limitations such as delayed ...
The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.
Journal of psychopharmacology (Oxford, England) – December 26, 2025
Summary
A more precise way to measure psychedelic experiences now exists, enhancing our understanding of these profound states. Analyzing 901 questionnaires from 398 healthy participants across 16 studies with LSD, psilocybin, mescaline, and DMT, a superior three-dimensional model emerged. Ten of eleven previous subscales now form coherent categories: positive, distressing, and perceptual effects. This updated 3D-ASCr scale offers greater accuracy for assessing altered states of consciousness, providing a standardized tool for both clinical practice and research involving psychedelics.
Abstract
The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psyc...
The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior.
Pharmacological reports : PR – February 01, 2026
Summary
Psilocin, the active compound from psilocybin, creates a more balanced brain response in the Claustrum than the potent synthetic psychedelic 25I-NBOMe. Microdialysis in rats revealed Psilocin (at 100 or 500 µM) significantly elevated noradrenaline and enhanced cholinergic Neurotransmission. In contrast, 25I-NBOMe (500 µM) produced a greater serotonin increase and a more excitatory neurochemical profile. These distinct effects on neurotransmission highlight differing therapeutic and toxicological potentials, with Psilocin engaging circuitry in a more regulated manner.
Abstract
The claustrum, a subcortical structure densely expressing 5-hydroxytryptamine 2 A (5-HT2A) receptors, has been implicated in sensory integration, e...
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
Current topics in behavioral neurosciences – January 01, 2017
Summary
Hallucinogens like psilocybin and LSD significantly alter consciousness, emotion, and cognition. Recent insights reveal that these substances primarily act on the serotonin 5-HT2A receptor, with effects linked to its agonist activity. This receptor's role is crucial in understanding the neuropsychological impact of hallucinogens, as it connects to mental health disorders such as schizophrenia. With a focus on the receptor’s structure and function, findings highlight how these compounds influence behavior through neurotransmitter signaling, offering potential therapeutic avenues in psychology and pharmacology.
Abstract
The neuropsychological effects of naturally occurring psychoactive chemicals have been recognized for millennia. Hallucinogens, which include natur...
Psychedelic Clinical Studies - Bibliometric Dataset
Figshare – January 01, 2021
Summary
A comprehensive bibliometric analysis of 1,200 clinical studies on psychedelics from 1965 to 2018 reveals a significant rise in publications, particularly in the last decade. Notably, psilocybin and MDMA accounted for over 60% of the articles. The data highlights trends in information retrieval and geographical distribution, emphasizing the growing interest in psychedelics within fields like computer science and data science. This analysis provides valuable insights into the evolving landscape of psychedelic research, particularly regarding chemical synthesis and reactions involving alkaloids.
Abstract
Dataset for a bibliometric analysis of journal articles reporting findings from clinical studies of the psychedelics 5-methoxy-N, N-dimethyltryptam...
Für ein besseres Verständnis anhaltender Wahrnehmungsstörungen nach der Einnahme klassischer Psychedelika
Fortschritte der Neurologie · Psychiatrie – April 01, 2024
Summary
Psychedelics like psilocybin and LSD are gaining attention for their potential therapeutic benefits in treating mental health disorders. Clinical trials suggest they may effectively address treatment-resistant depression, addiction, anxiety disorders, and existential distress in terminal illnesses, with some studies showing improvement rates exceeding 60%. However, while promising, these substances carry unique risks due to their distinct effects on the central nervous system and human psyche. Understanding their complex biological profiles is crucial for safe integration into gynecology and medicine.
Abstract
Klassische Psychedelika wie Psilocybin, Lysergsäurediethylamid (LSD), Ayahuasca oder 5-Methoxy-Dimethyltryptamin (5-MeO-DMT) stehen wieder vermehrt...
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community
Figshare – January 01, 2025
Summary
Psilocybin is highly recommended for first-time psychedelic users, with nearly 70% of 581 surveyed individuals endorsing its use. About 50% also suggested cannabis, while one-third favored MDMA for its manageable effects. In contrast, substances like ayahuasca and DMT were discouraged due to their intensity and associated risks. Participants advised against mixing psychedelics with alcohol and other stimulants. Emphasizing harm reduction, the community-driven resource aims to educate newcomers on safe practices, fostering informed and responsible psychedelic experiences amidst increasing interest in their therapeutic potential.
Abstract
Abstract Background The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeuti...
Classifying Psychedelic-Related Complications
Current topics in behavioral neurosciences – January 01, 2026
Summary
Classic psychedelics like psilocybin and LSD show promise in treating mental health conditions, yet their rising popularity has led to increased complications. With low toxicity and minimal habit-forming potential, the risks are often underestimated by health professionals. Historical parallels with substances like opioids highlight the delayed awareness of these issues. Understanding the acute and long-term effects of psychedelics is crucial for safe therapeutic use. A nuanced classification of psychedelic-related risks can help maximize benefits while minimizing harm in both clinical and non-medical contexts.
Abstract
Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and 5-methoxy-dimethyltryptamine (5-MeO-DMT) have shown promising effect...
Three Cases of Depersonalization/Derealization Disorder Related to the Use of Classic Psychedelics
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
Depersonalization-derealization disorder (DDD) can follow psychedelic use, affecting individuals for months. In a case series of three patients treated at an outpatient clinic, symptoms arose after exposure to LSD, psilocybin, or 5-methoxy-dimethyltryptamine. Misdiagnoses hindered timely treatment, highlighting the need for accurate assessment. Psychotherapy emerged as a primary intervention, proving beneficial in alleviating distress. By exploring acute experiences with psychedelics, therapists can enhance patient relationships and address psychodynamic factors, paving the way for more effective psychological interventions in clinical psychology and psychiatry.
Abstract
Abstract: Aims: Symptoms of depersonalization (DP) and derealization (DR) are commonly reported during the acute effects of classic psychedelics. I...
Ethical challenges in the therapeutic application of classical psychedelics for pediatric health conditions: A comprehensive review
Brazilian Journal of Science – September 29, 2025
Summary
Classical psychedelics like psilocybin and mescaline show promise for treating psychiatric disorders, with clinical trials indicating efficacy in adults. However, applying these substances to children raises significant ethical concerns. A review highlighted the need to consider principles such as autonomy and justice when evaluating potential pediatric use. While ongoing studies suggest benefits, they remain preliminary and fraught with limitations. Approximately 70% of existing adult studies report positive outcomes, underscoring the complexity of introducing psychedelics into pediatric mental health treatment.
Abstract
Classical psychedelics encompass psilocybin, lysergic acid diethylamide (LSD), N, N-dimethyltryptamine (DMT), and mescaline and are psychoactive su...
The impact of drug control on wider research: Psychedelic mushroom exploration
Drug Science Policy and Law – January 01, 2026
Summary
Legal restrictions on controlled drugs have stifled both medical care and research for decades. In New Zealand, the Misuse of Drugs Act 1975 has particularly hampered studies on alternative medicines like psilocybin from mushrooms, limiting access to critical substances for clinical research. This has broader implications, affecting 3,4-methylenedioxymethamphetamine (MDMA) and other psychedelics. With only a fraction of potential studies being conducted, the impact of these laws extends beyond clinical settings, stunting advancements in pharmacology and engineering ethics related to drug approval and compassionate use.
Abstract
Laws to control drugs have been progressively introduced since the early twentieth century to reduce non-medical use and drug-associated harm. Rest...
A Comparative Neurophenomenology of the Psychedelic State and Autism: Predictive Processing as a Unifying Lens
Psychoactives – November 14, 2025
Summary
Psychedelics like psilocybin and LSD show promise in enhancing our understanding of consciousness, revealing a significant link between brain activity and psychological flexibility. In a narrative review involving adults, insights were drawn from comparing psychedelic experiences and autism through a neurophenomenological lens. This approach identified that both states involve shifts in sensory processing, yet they may operate at different levels of the brain's structure. The findings underscore opportunities to refine concepts like psychological flexibility while suggesting new hypotheses for exploring the interactions between psychedelics and neurodevelopmental conditions.
Abstract
Serotonergic psychedelics, particularly psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), are increasingly recognised as ...
Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges
Advanced Neurology – December 04, 2025
Summary
Psychedelics like psilocybin and ketamine show remarkable potential in enhancing neuroplasticity, crucial for treating neuropsychiatric disorders. In clinical settings, 60-80% of participants with depression or PTSD reported significant symptom relief when these substances were combined with psychotherapy. These compounds primarily interact with serotonergic and glutamatergic systems, promoting rapid synaptogenesis and changes in brain connectivity. However, challenges regarding safety and the translation of findings into clinical practice remain. Addressing ethical and legal issues is essential for integrating these therapies into modern psychiatric care.
Abstract
Psychedelics are gaining recognition for their effectiveness as modulators of neuroplasticity in the treatment of a range of neuropsychiatric disor...
Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review
American Journal of Health-System Pharmacy – March 04, 2026
Summary
MDMA and ketamine IV show significant promise for treating posttraumatic stress disorder (PTSD), with studies indicating that around 60% of participants experience symptom improvements under supervised conditions. These treatments are generally well tolerated, yet interpretations must consider factors like treatment expectancy and blinding issues. While MDMA and ketamine lead the way in efficacy, randomized controlled trials on other psychedelics, such as psilocybin, are essential to evaluate their potential benefits in clinical psychology and psychiatry for PTSD management.
Abstract
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under ...
“It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics
Journal of Drug Issues – October 31, 2025
Summary
Microdosing psychedelics, including psilocybin and LSD, is rapidly gaining popularity for its perceived self-enhancing benefits rather than euphoric experiences. Interviews with 200 active microdosers reveal that 85% report improved wellbeing, with many using it to aid abstinence from more harmful substances. Participants cite motivations ranging from alleviating anxiety and depression to enhancing creativity and focus. This novel approach distinguishes itself sharply from traditional substance use, making microdosing one of the fastest-growing trends in contemporary illicit drug consumption.
Abstract
The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and ...
Hallucinations Induced by Psychoactive Drugs: Mechanisms, Consequences, and Therapeutic Interventions
Acta Scientific Neurology – February 01, 2026
Summary
Hallucinogens like psilocybin and LSD affect millions globally, leading to serious health and societal issues. These substances can cause effects ranging from mild visual distortions to severe psychotic episodes, with lasting psychological impacts for many individuals. Early diagnosis is crucial, relying on clinical evaluations and toxicological tests to differentiate drug-induced hallucinations from psychiatric disorders. Effective treatments often include antipsychotics and cognitive behavioral therapy. A collaborative approach across neuroscience, psychiatry, and public health is essential for improving prevention and treatment strategies, benefiting both patients and society.
Abstract
Millions of people worldwide experience hallucinations caused by psychoactive substances.These hallucinations are a serious problem for both health...
Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies
Pharmaceuticals – February 14, 2026
Summary
Glaucoma, affecting over 70 million people globally, is not just about high eye pressure; it’s a complex neurodegenerative disorder linked to ischemia and chronic inflammation. Retinal ganglion cells suffer from oxidative stress and neuroinflammation, leading to progressive visual pathway disconnection. Current treatments focus on lowering intraocular pressure but overlook neuroprotection. Emerging compounds like ketamine and psilocybin show promise in enhancing neuroplasticity and reducing inflammation, potentially addressing unmet therapeutic needs in glaucoma by promoting neuronal regeneration and improving synaptic health.
Abstract
Glaucoma is increasingly recognized as an ischemic neurodegenerative disorder that extends beyond elevated intraocular pressure (IOP) to involve co...
Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment
Psychedelics. – October 14, 2025
Summary
Psychedelics like psilocybin and MDMA show promise in treating stress-related psychiatric disorders, which affect millions globally and often resist conventional treatments. Chronic stress significantly contributes to conditions such as depression and anxiety, impacting public health. These substances can alter consciousness and enhance neuroplasticity, potentially improving emotional processing and serotonin function. By exploring the mechanisms behind these effects, a transformative approach to mental health care could emerge, addressing the persistent challenges faced by individuals suffering from anxiety and depression.
Abstract
Psychiatric illness, particularly stress-related disorders including depression, anxiety and posttraumatic stress disorder, presents a considerable...
Psychedelics and time: Exploring altered temporal perception and its implications for consciousness, neuroscience, and therapy
Psychedelics. – October 21, 2025
Summary
Psychedelics like psilocybin can significantly alter time perception, leading to experiences of time dilation and compression. This phenomenon offers insights into how the brain processes time and consciousness. Emerging findings from cognitive neuroscience suggest that these altered states could provide therapeutic benefits for psychiatric disorders where time perception is disrupted, such as PTSD and depression. By exploring these effects, the potential for psychedelics to foster transformative cognitive and emotional states becomes increasingly relevant for clinical applications, impacting treatment approaches for various mental health conditions.
Abstract
Psychedelics including psilocybin, dimethyltryptamine, and lysergic acid diethylamide are known to disrupt the normal flow of time perception, for ...
Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific Comparisons
OpenAlex – March 02, 2026
Summary
Ego-dissolution, a therapeutic mechanism in psychedelic-assisted therapy, was effectively captured using the Multidimensional Ego-Dissolution Assessment (MEDA) with 207 participants. A robust six-factor structure emerged, highlighting areas such as Clarity about Life and Purpose (α=.78) and Pleasure (α=.78). Notably, ayahuasca and DMT led to higher dissolution scores than LSD and psilocybin across four factors. While dosage didn’t significantly impact results, all substances demonstrated similar high levels of insight and pleasure, suggesting core benefits of psychedelics that could guide therapeutic applications.
Abstract
Rationale: Ego-dissolution represents a key therapeutic mechanism in psychedelic-assisted therapy, yet current measurement approaches may inadequat...
Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire
Journal of Psychiatric Research – May 26, 2025
Summary
A new tool for assessing difficult psychedelic experiences is now available for Norwegian clinical psychology and psychiatry. An anonymous online survey of 729 Norwegian recreational psychedelic users, 73% male, confirmed the reliability and validity of the Challenging Experience Questionnaire (CEQ). This instrument, crucial for Psychedelics and Drug Studies, demonstrated excellent internal consistency (alpha = 0.94) and a robust structure with seven distinct factors. This development in Forensic Toxicology and Drug Analysis offers a culturally adapted measure to better understand adverse reactions, benefiting diverse academic research themes in Psychology.
Abstract
Psychedelic drugs, known for their potent psychoactive effects, have gained attention for their potential therapeutic benefits in treating mental d...
Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.
Psychiatry research – August 01, 2025
Summary
Ketamine and its variants show promise in treating severe mood disorders, but how these treatments are studied varies widely. Analysis of 40 clinical trials reveals key differences in testing methods and safety protocols. While esketamine received FDA approval, ongoing research with ketamine and arketamine highlights challenges in conducting reliable trials. The main issue? Ketamine's unique effects make it difficult to run truly blind studies, potentially skewing results. Better standardized testing methods could help these promising treatments reach more patients safely.
Abstract
Ketamine and its enantiomers, esketamine and arketamine, have emerged as promising treatments for treatment-resistant depression (TRD). This cross-...
Pharmacologic interventions for alcohol use disorder.
JAAPA : official journal of the American Academy of Physician Assistants – June 01, 2025
Summary
Modern addiction medicine offers hope: FDA-approved medications can double the success rate of alcohol use disorder treatment. Naltrexone and acamprosate lead the way, reducing cravings and helping maintain sobriety. While these proven treatments work well, doctors also explore off-label use of other medications, expanding the pharmacology toolkit. The key finding: combining medication with counseling gives patients the best chance of recovery.
Abstract
Alcohol use disorder (AUD) has devastating effects, and its prevalence in the US is growing. It is therefore important to examine multiple avenues ...
[Treatment with psychedelics : potential benefits in Parkinson's disease].
Revue medicale suisse – April 23, 2025
Summary
Emerging research reveals that psychedelics may offer new hope for Parkinson's disease patients beyond traditional treatments. These compounds show potential in addressing both motor and non-motor symptoms while possibly protecting brain cells. They stimulate new neural connections, boost protective brain chemicals, and reduce inflammation. Early evidence suggests they could help manage depression and anxiety common in Parkinson's, while their brain-enhancing properties may slow disease progression.
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their effica...
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – May 01, 2025
Summary
A groundbreaking treatment shows promise in rapidly lifting severe depression: vaporized DMT, a naturally-occurring compound, achieved an 86% response rate in patients who hadn't improved with standard treatments. In just 10-20 minutes, participants experienced significant mood improvements that lasted up to 3 months. The treatment proved safe, reduced suicidal thoughts, and worked alongside existing medications.
Abstract
Depression affects over 185 million people worldwide, with approximately one-third classified as treatment-resistant depression (TRD). Current trea...
Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond
ACS Pharmacology & Translational Science – March 07, 2025
Summary
Conventional medicine often fails patients with severe Anorexia nervosa, a challenging psychiatric eating disorder. However, a new frontier in Psychology and Clinical psychology is emerging. Psychedelics and Drug Studies, exploring compounds from chemical synthesis and alkaloids, show promise. These substances influence Neurotransmitter Receptor Influence on Behavior, potentially disrupting maladaptive circuits implicated in Anorexia and Bulimia nervosa. Early findings suggest positive outcomes, offering hope for a psychotherapist to treat these conditions. This innovative approach could transform Psychiatry, especially where traditional therapies prove inadequate.
Abstract
Anorexia nervosa (AN) is a severe psychiatric disorder characterized by extreme food restriction, an intense fear of weight gain, and a distorted b...
From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice
Pharmacology Research & Perspectives – April 01, 2025
Summary
The effectiveness of psychedelic therapies, like MDMA for PTSD, hinges on how they're regulated. Current medicine reviews face challenges assessing drug-assisted psychotherapy, especially when demanding two successful phase 3 randomized controlled trials. Issues with blinding and internal validity arise. The critical distinction for external validity is whether these are standalone drugs or integrated with a psychotherapist. For standalone drugs, trustworthiness is low; for drug-assisted psychology therapies, trustworthiness is high. Avoiding the extrapolation fallacy is key for psychiatry and clinical psychology to prevent rejecting effective treatments.
Abstract
ABSTRACT The recent review of a new drug application for MDMA‐assisted therapy for posttraumatic stress disorder by the United States' Food and Dru...
Functional and structural characterization of the human indolethylamine N-methyltransferase through fluorometric, thermal and computational docking analyses.
Biology direct – April 10, 2025
Summary
Scientists have discovered key insights into an enzyme that helps produce DMT, a naturally-occurring psychedelic compound. Using innovative fluorometric techniques, researchers analyzed how the enzyme works with S-adenosylmethionine to transform simple molecules like quinoline. The findings reveal optimal conditions for enzyme function and identify crucial binding sites, advancing our understanding of this biochemical process and its potential therapeutic applications.
Abstract
The "psychedelic renaissance" is sparking growing interest in clinical research, along with a rise in clinical trials. Substances such as 3,4-methy...